Profile data is unavailable for this security.
About the company
Biocon Limited is an India-based biopharmaceutical company, engaged in the manufacture of biotechnology products and research services. The Company is in the business of manufacturing active pharmaceutical ingredients (APIs) and formulations, including biosimilar drugs for diabetics, oncology and autoimmune diseases. The Company’s segment includes Generics, Biosimilars, Novel Biologics and Research Services. It focuses on three key therapeutic areas - Diabetes, Oncology and Immunology. Its APIs pipeline includes cardiovascular, anti-diabetics, immunosuppressants, and specialty molecules. Its products include Tacrolimus, Rosuvastatin, Simvastatin, Atorvastatin, Pravastatin, Fingolimod and others. Its APIs manufacturing facilities with capabilities in microbial fermentation, downstream process, including chromatographic purification, chemical synthesis, peptide synthesis and Highly Potent APIs (HPAPIs). It has over five facilities in Bangalore, Hyderabad and Visakhapatnam in India.
- Revenue in INR (TTM)148.94bn
- Net income in INR14.39bn
- Incorporated1978
- Employees3.68k
- LocationBiocon Ltd20th KM, Hosur Road, Electronic City,BANGALORE 560100IndiaIND
- Phone+91 8 028082808
- Fax+91 8 028523423
- Websitehttps://www.biocon.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sinocelltech Group Ltd | 28.47bn | -286.88m | 209.37bn | 2.33k | -- | -- | -- | 7.35 | -0.0553 | -0.0553 | 5.49 | -0.2874 | 0.8146 | 0.4624 | 5.26 | 1,048,041.00 | -0.8674 | -40.17 | -2.70 | -74.63 | 95.83 | 95.42 | -1.06 | -108.20 | 0.588 | 5.45 | 1.05 | -- | 84.46 | 264.19 | 23.70 | -- | 37.54 | -- |
| Dizal Pharmaceutical Co Ltd | 4.54bn | -9.75bn | 225.81bn | 581.00 | -- | 45.27 | -- | 49.78 | -2.04 | -2.04 | 0.9471 | 1.03 | 0.235 | 0.4033 | 6.15 | 670,632.10 | -56.00 | -46.02 | -83.89 | -52.99 | 97.17 | 57.53 | -238.28 | -2,081.54 | 1.66 | -193.39 | 0.674 | -- | -- | 18.29 | -50.50 | -- | 21.35 | -- |
| Genscript Biotech Corp | 85.17bn | -14.93bn | 247.84bn | 7.28k | -- | 2.41 | -- | 2.91 | -0.6509 | -0.6509 | 3.72 | 4.45 | 0.3006 | 9.15 | 7.99 | 1,132,728.00 | -9.68 | -18.34 | -14.76 | -26.15 | 53.63 | 54.68 | -32.19 | -64.91 | 4.06 | -- | 0.1972 | -- | 34.17 | 29.44 | 57.91 | -- | 17.14 | -- |
| Shanghai Allist Pharmaceuticals Co Ltd | 37.30bn | 15.10bn | 295.34bn | 1.04k | 19.56 | 5.22 | -- | 7.92 | 2.88 | 2.88 | 7.12 | 10.81 | 0.6811 | 3.60 | 11.38 | 3,068,832.00 | 27.57 | 0.6405 | 30.38 | 0.6933 | 94.43 | 96.42 | 40.47 | 2.54 | 6.89 | -- | 0.0003 | 211.88 | 155.14 | 237.34 | 393.54 | -- | 13.53 | -- |
| Syngene International Ltd | 34.51bn | 4.82bn | 341.33bn | 6.51k | 70.99 | 7.77 | 37.15 | 9.89 | 11.98 | 11.98 | 85.80 | 109.56 | 0.576 | 3.71 | 7.65 | 5,301,229.00 | 8.04 | 8.62 | 9.82 | 11.43 | 73.62 | 71.13 | 13.96 | 16.22 | 1.81 | 9.91 | 0.1265 | -- | 9.26 | 13.83 | 9.82 | 8.99 | -2.62 | 20.11 |
| Biocon Ltd | 148.94bn | 14.39bn | 391.69bn | 3.68k | 27.20 | 1.87 | 11.15 | 2.63 | 12.02 | 12.02 | 123.54 | 174.86 | 0.2667 | 0.9977 | 2.93 | 40,462,100.00 | 3.34 | 3.20 | 5.01 | 4.48 | 66.92 | 62.04 | 12.52 | 9.37 | 0.6446 | 1.53 | 0.3856 | 8.22 | 32.05 | 21.76 | 120.99 | 2.46 | 5.30 | 0.00 |
| Sichuan Kelun-Biotech Biophrmctcl Co Ltd | 21.88bn | -2.71bn | 415.68bn | 1.54k | -- | 11.11 | -- | 19.00 | -1.11 | -1.11 | 9.12 | 15.48 | 0.5869 | 9.46 | 167.74 | 1,426,347.00 | -7.28 | -- | -16.56 | -- | 61.81 | -- | -12.40 | -- | 5.59 | -- | 0.0118 | -- | 91.62 | -- | 6.81 | -- | -- | -- |
| Telix Pharmaceuticals Ltd | 35.44bn | 2.70bn | 421.74bn | 234.00 | 153.37 | 19.00 | 136.17 | 11.90 | 0.1497 | 0.1497 | 1.96 | 1.21 | 1.22 | 11.36 | 8.61 | -- | 9.31 | -29.08 | 15.01 | -40.27 | 61.80 | 61.64 | 7.62 | -37.14 | 0.8687 | -- | 0.052 | -- | 213.90 | 381.02 | 105.01 | -- | -- | -- |
| PharmaEssentia Corp | 21.59bn | 4.79bn | 517.09bn | 131.00 | 103.74 | 7.44 | 89.71 | 23.95 | 5.63 | 5.63 | 25.28 | 78.50 | 0.297 | 0.7657 | 4.68 | -- | 6.59 | -16.79 | 7.12 | -19.66 | 87.10 | 76.47 | 22.19 | -79.56 | 11.67 | -- | 0.0377 | -- | 77.15 | 186.97 | 54.62 | -- | 66.34 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Life Insurance Corporation of India (Investment Portfolio)as of 13 Sep 2024 | 60.31m | 5.02% |
| SBI Funds Management Ltd.as of 31 Oct 2024 | 29.04m | 2.42% |
| Kotak Mahindra Asset Management Co. Ltd.as of 31 Oct 2024 | 19.04m | 1.59% |
| Arohi Asset Management Pte Ltd.as of 17 Mar 2023 | 18.95m | 1.58% |
| The Vanguard Group, Inc.as of 06 Nov 2024 | 16.77m | 1.40% |
| ICICI Prudential Asset Management Co. Ltd.as of 31 Oct 2024 | 9.87m | 0.82% |
| SBI Life Insurance Co. Ltd. (Investment Portfolio)as of 31 Aug 2024 | 6.81m | 0.57% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 6.37m | 0.53% |
| BlackRock Fund Advisorsas of 07 Nov 2024 | 5.96m | 0.50% |
| JM Financial Asset Management Ltd.as of 31 Oct 2024 | 5.32m | 0.44% |
